Skip to main content
. 2017 Dec 9;9(3):3043–3059. doi: 10.18632/oncotarget.23077

Figure 3. Dose dependent suppression in the average growth of glioma stem cell populations by a TOPK inhibitor OTS964.

Figure 3

(A and B), Consistent growth of U87 (A) or U251 (B) -derived GSC clones in the methylcellulose-containing growth media. The average number of cells/clone is shown at each time point (at 0, 4, 7 days for A and B; 14, 21, 28 days for B, respectively). The experiments were repeated for 5 generations (1st shown in black filled circles; 2nd: blue; 3rd: green; 4th: orange; 5th: red, respectively). (C–N), Dose dependent suppression in the growth of clones in the presence of a TOPK inhibitor OTS964 (Oncotherapy Science). The average numbers of cells/clone among all clones (C–E); among self-renewed clones (F–H for clones with multiple cells); among expanded clones (I–K) for clones with more than 4 cells; (L–N) for clones with more than 9 cells) are shown at various concentrations of OTS964 (0; 20; 100; 200; 500 nM). The graphs are for U87 (C, F, I and L) and for U251 (D, E, G, H, J, K, M and N) -derived GS clones. The data at 20, 100 and 500 nM were taken from the first experiment; 200 nM from the second; 300 nM from the third and fourth and the control (0 nM) from the first through the fourth, respectively. Existence of OTS964 suppressed the growth of GS clones, and the effects were dose-dependent.